Skip to main content

Table 1 Significant pathways from top 250 predictor genes associated with response to PG-11047 treatment using Ingenuity Pathway analysis.

From: A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047

Pathway Name

P-Value

Ratio

Component genes in the pathway

Interferon Signaling

0.001

[4/29]

IRF1, IRF9, TAP1, IFNGR1

Ephrin Receptor Signaling

0.011

[8/193]

CXCR4, ABI1, RAP1A, MAPK1, WASL,

MAP4K4, GNAI3, PAK1

Role of BRCA1 in DNA Damage

Response

0.013

[4/52]

RPA1, RFC3, MSH2, E2F3

Nicotinate and Nicotinamide

Metabolism

0.019

[5/129]

NNMT, ENPP2, MAPK1, ENPP1, PAK1

Fcy Receptor -mediatedPhagocytosis in Macrophages andMonocytes

0.028

[5/104]

RPS6KB1, LYN, MAPK1, VAMP3, PAK1

Riboflavin Metabolism

0.032

[2/49]

ENPP2, ENPP1

Endoplasmic Reticulum Stress

Pathway

0.041

[2/18]

XBP1, TAOK3

Pantothenateand CoA Biosynthesis

0.046

[2/63]

ENPP2, ENPP1

CXCR4 Signaling

0.052

[6/164]

CXCR4, RHOB, LYN, MAPK1, GNAI3, PAK1

PI3K/AKT Signaling

0.055

[5/135]

RPS6KB1, SFN, MAPK1, YWHAH, PPP2R5A

Integrin Signaling

0.056

[7/198]

RHOB, RAP1A, MAPK1, TSPAN6, WASL, ARF4, PAK1

  1. Ratio indicates the number of genes in the top 250 predictors that belong to the pathway indicated over the number of genes known of the pathway. Genes in bold were associated with resistance when transcribed at high levels. Genes in normal fonts were associated with sensitivity when transcribed at high levels.